US 11,945,833 B2
Prodrugs of L-BHDU and methods of treating viral infections
Uma Sharan Singh, Athens, GA (US); and Chung Chu, Duluth, GA (US)
Assigned to University of Georgia Research Foundation, Inc., Athens, GA (US); and Anterogen Co., Ltd., Seoul (KR)
Filed by UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., Athens, GA (US); and Anterogen Co., Ltd, Seoul (KR)
Filed on Oct. 28, 2022, as Appl. No. 17/976,407.
Claims priority of provisional application 63/273,403, filed on Oct. 29, 2021.
Prior Publication US 2023/0167143 A1, Jun. 1, 2023
Int. Cl. C07F 9/6558 (2006.01); A61K 31/675 (2006.01); A61K 45/06 (2006.01); A61P 31/22 (2006.01)
CPC C07F 9/65586 (2013.01) [A61K 31/675 (2013.01); A61K 45/06 (2013.01); A61P 31/22 (2018.01)] 42 Claims
 
1. A prodrug compound of L-BHDU according to the chemical structure I:

OG Complex Work Unit Chemistry
Where R1 is a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group;
R2 is H, a —(CH2)n—O—R1a group or a —(CH2)j—O—C(O)Ok—R2a group;
R1a is independently a C6-C30 alkyl group, often a C12-C22 alkyl group, often a C14-C20 alkyl group or a C16-C18 alkyl group, often a C16 or C18 alkyl group;
R2a is independently a C1-C12 alkyl group, often a C2-C6 alkyl group, a C3-C4 alkyl group, an isopropyl, t-butyl or sec-butyl group, or an isopropyl or t-butyl group;
Each j is independently 1-6, 1-3, often 1 or 2;
Each k is 0 or 1;
Each n is independently 1-6; or
A pharmaceutically acceptable salt, solute or polymorph thereof.